AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19026203 — intervention group
Group type: EXPERIMENTAL
Intervention: Two axial Kirschner wire fixation (Group I)
Number of subjects: 65
Study 19026203 — intervention group
Group type: COMPARATOR
Intervention: Two axial and supplementary transverse Kirschner wire fixation (Group II)
Number of subjects: 65
Study 16002492 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group (3D computer-assisted localization)
Number of subjects: 50
Study 16002492 — intervention group
Group type: COMPARATOR
Intervention: Feedback group (therapist feedback localization)
Number of subjects: 50
Study 12832372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) plus a paracervical block (PCB)
Number of subjects: 286
Study 12832372 — intervention group
Group type: COMPARATOR
Intervention: alfentanil plus a paracervical block (PCB)
Number of subjects: 286
Study 10392878 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patches of estradiol‐17beta
Number of subjects: 6
Study 10392878 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6
Study 8730807 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching motion-defined static and moving objects
Number of subjects: 0
Study 1669587 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/12 h for 4 weeks and 200 micrograms/12 h for 4 more weeks
Number of subjects: 28
Study 1669587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6841631 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians who received a warning regarding the error of assessing art ability
Number of subjects: 64
Study 6841631 — intervention group
Group type: COMPARATOR
Intervention: Clinicians who did not receive a warning regarding the error of assessing art ability
Number of subjects: 64
Study 31918739 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention for parents
Number of subjects: 200
Study 31918739 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management and preschool teacher training
Number of subjects: 200
Study 31918739 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 31115348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention
Number of subjects: 60
Study 28905172 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban (80 mg once daily for 35-42 days)
Number of subjects: 3261
Study 28905172 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care enoxaparin (40 mg once daily for 10±4 days)
Number of subjects: 3261
Study 25752889 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 0.75 mg
Number of subjects: 10
Study 25752889 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 1.5 mg
Number of subjects: 10
Study 25752889 — intervention group
Group type: EXPERIMENTAL
Intervention: THC pharmacokinetics
Number of subjects: 10
Study 25752889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23312704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp2‐2 genotype with elevated HbA(1c) (≥ 6.5%)
Number of subjects: 407
Study 23312704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp2‐2 genotype with HbA(1c) <6.5%
Number of subjects: 407
Study 21333015 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based psychological intervention (cognitive-behavioural models); 11 weekly sessions and 3 booster sessions.
Number of subjects: 2600
Study 21333015 — intervention group
Group type: COMPARATOR
Intervention: Usual but enhanced counselling sessions in control schools.
Number of subjects: 2600
Study 19875762 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention (10 in-person at home and 4 telephone sessions over 6 months)
Number of subjects: 150
Study 19875762 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 150
Study 19875762 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 150
Study 18044100 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 23
Study 18044100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15156769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency noise (LFN) at 50 dB(A)
Number of subjects: 193
Study 15156769 — intervention group
Group type: COMPARATOR
Intervention: Broadband noise at comparable levels of 50 dB(A)
Number of subjects: 193
Study 15156769 — intervention group
Group type: COMPARATOR
Intervention: Background laboratory noise of about 30 dB(A)
Number of subjects: 193
Study 11505744 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg once daily)
Number of subjects: 176
Study 11505744 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5-20 mg once daily)
Number of subjects: 176
Study 9385238 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (proximal realignment procedures)
Number of subjects: 125
Study 9385238 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 125
Study 7957511 — intervention group
Group type: COMPARATOR
Intervention: 10 mg isosorbide dinitrate (ISDN)
Number of subjects: 16
Study 7957511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg pirsidomine
Number of subjects: 16
Study 7957511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pirsidomine
Number of subjects: 16
Study 7957511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2890307 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted medication plus psychosocial intervention
Number of subjects: 42
Study 2890307 — intervention group
Group type: COMPARATOR
Intervention: Continuous medication
Number of subjects: 42
Study 29661990 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic noise
Number of subjects: 83
Study 29661990 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest birdsong
Number of subjects: 83
Study 29661990 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no auditory stimuli)
Number of subjects: 83
Study 28466749 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment intervention (6 weeks of information booklets and face-to-face discussions)
Number of subjects: 112
Study 26490492 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary resveratrol plus total urinary resveratrol (TDR + TUR)
Number of subjects: 769
Study 26490492 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 769
Study 23964932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg) intravenously at weeks 0 and 2
Number of subjects: 895
Study 23964932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 8 weeks
Number of subjects: 895
Study 23964932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 895
Study 23964932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study 20615906 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-enriched dialysate (3 mEq/L)
Number of subjects: 24
Study 20615906 — intervention group
Group type: COMPARATOR
Intervention: Conventional saline flushing
Number of subjects: 24
Study 18447215 — intervention group
Group type: EXPERIMENTAL
Intervention: Point sticking therapy (Sanleng, Ezhu, Zhi Nanxing, Bingpian applied to Qihai, Guanyuan, and Ashi points)
Number of subjects: 63
Study 18447215 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Rupixiao (control group)
Number of subjects: 63
Study 18447215 — intervention group
Group type: EXPERIMENTAL
Intervention: Point sticking therapy
Number of subjects: 63
Study 16324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 45 mg
Number of subjects: 0
Study 16324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (25 mg TID) plus caffeine (200 mg TID)
Number of subjects: 0
Study 16324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pioglitazone + Ephedrine + Caffeine)
Number of subjects: 0
Study 14615440 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture at points with electrodermal signal
Number of subjects: 90
Study 14615440 — intervention group
Group type: COMPARATOR
Intervention: Placebo auricular acupuncture at points with no electrodermal signal
Number of subjects: 90
Study 14615440 — intervention group
Group type: COMPARATOR
Intervention: Placebo auricular seeds fixed at placebo points
Number of subjects: 90
Study 11037586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 11037586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 0
Study 11037586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0
Study 11037586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0
Study 9366532 — intervention group
Group type: EXPERIMENTAL
Intervention: Torso phased‐array (TPA) coil with four acquisitions
Number of subjects: 60
Study 9366532 — intervention group
Group type: EXPERIMENTAL
Intervention: Torso phased‐array (TPA) coil with two acquisitions
Number of subjects: 60
Study 9366532 — intervention group
Group type: COMPARATOR
Intervention: Body coil with four acquisitions
Number of subjects: 60
Study 9366532 — intervention group
Group type: EXPERIMENTAL
Intervention: Body coil and TPA coil
Number of subjects: 60
Study 1389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 x 10(6) IU)
Number of subjects: 128
Study 1389731 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30U)
Number of subjects: 128
Study 4017422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous felodipine (2.5 mg infusion over 30 minutes)
Number of subjects: 8
Study 4017422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral felodipine (27.5 mg solution)
Number of subjects: 8
Study 30963811 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent self-affirmation
Number of subjects: 186
Study 30963811 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdependent self-affirmation
Number of subjects: 186
Study 30963811 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between self-affirmation type and self-construal
Number of subjects: 186
Study 29852045 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenopharyngoplasty (APP)
Number of subjects: 83
Study 29852045 — intervention group
Group type: COMPARATOR
Intervention: Adenotonsillectomy (ATE)
Number of subjects: 83
Study 26605955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies by community health workers
Number of subjects: 23
Study 26605955 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies by community health workers
Number of subjects: 23
Study 25384797 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated graphic symbols with environmental sounds
Number of subjects: 46
Study 25384797 — intervention group
Group type: COMPARATOR
Intervention: Animated graphic symbols without environmental sounds
Number of subjects: 46
Study 22570363 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Number of subjects: 225
Study 22570363 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 225
Study 22570363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 22570363 — intervention group
Group type: COMPARATOR
Intervention: Post hoc analysis
Number of subjects: 225
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Catholic religious affiliation
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuban-American ethnicity
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S.-born status
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher acculturation
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: More education
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Never married status
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 2773
Study 20184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 2773
Study 17268946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Movement Chart (FMC) proposed by CLAP
Number of subjects: 1400
Study 17268946 — intervention group
Group type: COMPARATOR
Intervention: Count-to-10 method
Number of subjects: 1400
Study 16215339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg preoperatively
Number of subjects: 45
Study 16215339 — intervention group
Group type: COMPARATOR
Intervention: Placebo preoperatively
Number of subjects: 45
Study 12473552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous platelet GP IIb/IIIa inhibitors
Number of subjects: 627
Study 12473552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 9932951 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 9932951 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 0
Study 9932951 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 0
Study 7607719 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (54 mmol/d)
Number of subjects: 19
Study 7607719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2136871 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (4-9 mg)
Number of subjects: 30
Study 2136871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (100-225 mg)
Number of subjects: 30
Study 2136871 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 30
Study 2136871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30
Study 69290 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine (diacetylmorphine, heroin)
Number of subjects: 699
Study 69290 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 699
Study 69290 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine
Number of subjects: 699
Study 69290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic medication
Number of subjects: 699
Study 69290 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine and Morphine
Number of subjects: 699
Study 31356426 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE (SC) intervention
Number of subjects: 30
Study 31356426 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) intervention
Number of subjects: 30
Study 29658257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai Capsules (NMT)
Number of subjects: 240
Study 29658257 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hydrochloride (DH)
Number of subjects: 240
Study 29658257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai Capsules + Doxycycline hydrochloride (NMT+DH)
Number of subjects: 240
Study 25908066 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week clopidogrel therapy
Number of subjects: 614
Study 25908066 — intervention group
Group type: COMPARATOR
Intervention: 6-month clopidogrel therapy
Number of subjects: 614
Study 23636549 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 996
Study 21288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at ETsevo 3%
Number of subjects: 63
Study 21288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at ETsevo 3.5%
Number of subjects: 63
Study 21288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at ETsevo 4%
Number of subjects: 63
Study 21288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5-2 mg/kg
Number of subjects: 63
Study 21288215 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 19635155 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IABP therapy
Number of subjects: 221
Study 19635155 — intervention group
Group type: COMPARATOR
Intervention: Postoperative IABP therapy
Number of subjects: 221
Study 17306698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (US)
Number of subjects: 10
Study 17306698 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US)
Number of subjects: 10
Study 17306698 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 10
Study 17306698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 14742358 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctic Sun Temperature Management System (AS group)
Number of subjects: 29
Study 14742358 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (control group)
Number of subjects: 29
Study 12890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy for 2 months and amorolfine 5% solution nail lacquer for 6 months
Number of subjects: 90
Study 12890209 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole monotherapy (three pulses)
Number of subjects: 90
Study 10225576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 518
Study 10225576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g
Number of subjects: 518
Study 10225576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MU/m2/t.i.w. for 6 months
Number of subjects: 160
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MU/m2/t.i.w. for 12 months
Number of subjects: 160
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 MU/m2/t.i.w. for 6 months
Number of subjects: 160
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 MU/m2/t.i.w. for 12 months
Number of subjects: 160
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype III or V
Number of subjects: 160
Study 8730501 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype I or II
Number of subjects: 160
Study 2228842 — intervention group
Group type: EXPERIMENTAL
Intervention: One day course of injectable cefotaxime
Number of subjects: 116
Study 2228842 — intervention group
Group type: COMPARATOR
Intervention: Five day oral course of co-amoxyclav (amoxycillin plus clavulanic acid)
Number of subjects: 116
Study 637271 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol with 1% halothane and spontaneous respiration
Number of subjects: 0
Study 637271 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol with 1% halothane and controlled respiration
Number of subjects: 0
Study 637271 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol with 3% halothane and spontaneous respiration
Number of subjects: 0
Study 637271 — intervention group
Group type: COMPARATOR
Intervention: Halothane alone (without labetalol)
Number of subjects: 0
Study 31992234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy and case management (IPCM)
Number of subjects: 214
Study 31992234 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 214
Study 31267367 — intervention group
Group type: COMPARATOR
Intervention: JNJ-6379 (25 to 600 mg)
Number of subjects: 30
Study 31267367 — intervention group
Group type: COMPARATOR
Intervention: 150 mg JNJ-6379 twice daily for 2 days, followed by 100 mg JNJ-6379 daily for 10 days
Number of subjects: 30
Study 31267367 — intervention group
Group type: COMPARATOR
Intervention: JNJ-6379
Number of subjects: 30
Study 28377156 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein supplementation (2 × 15 g, twice daily) during 24 weeks of resistance-type exercise training
Number of subjects: 34
Study 28377156 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 24 weeks of resistance-type exercise training
Number of subjects: 34
Study 26412802 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide injected subcutaneously in the abdomen
Number of subjects: 60
Study 26412802 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide injected subcutaneously in the upper arm
Number of subjects: 60
Study 26412802 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide injected subcutaneously in the thigh
Number of subjects: 60
Study 26412802 — intervention group
Group type: COMPARATOR
Intervention: Period 2 versus Period 1
Number of subjects: 60
Study 26412802 — intervention group
Group type: COMPARATOR
Intervention: Period 3 versus Period 1
Number of subjects: 60
Study 26412802 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide injected in the abdomen
Number of subjects: 60
Study 23567307 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strains (Bifidobacterium lactis BB‐12 1 x 10^9 CFU and Streptococcus thermophilus TH‐4 1 x 10^8 CFU)
Number of subjects: 60
Study 23567307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 60
Study 20073999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 32
Study 20073999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 32
Study 20073999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine and Pentoxifylline
Number of subjects: 32
Study 20073999 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 32
Study 18851885 — intervention group
Group type: EXPERIMENTAL
Intervention: One of nine treatments for depression
Number of subjects: 243
Study 17522118 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 W bicycle exercise
Number of subjects: 0
Study 17522118 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% maximal power output (W(max)) bicycle exercise
Number of subjects: 0
Study 15198760 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine gel (20 cc) at the vaginal apex
Number of subjects: 1570
Study 15198760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no povidone-iodine gel)
Number of subjects: 1570